Chong Kun Dang makes joint sales of diabetes and hyperlipidemia treatments with MSD Korea

Published: 2016-01-06 15:30:04

Updated: 2016-01-06 15:30:04

On the 4^th, Chong Kun Dang(CEO Young-joo Kim) announced it made the joint sales agreement of 3 diabetes treatments and 2 hyperlipidemia treatments with MSD Korea.

Under the term of the agreement, Chong Kun Dang will jointly have domestic sales and marketing of 3 diabetes treatments(Januvia, Janumet and Janumet XR) and 2 hyperlipidemia treatments(Vytorin and Atozet) with MSD Korea from this Jan...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.

Chong Kun Dang makes joint sales of diabetes and hyperlipidemia treatments with MSD Korea

On the 4th, Chong Kun Dang(CEO Young-joo Kim) announced it made the joint sales agreement of 3 diabetes treatments and 2 hyperlipidemia treatments with MSD Korea.

Fees

On the 4^th, Chong Kun Dang(CEO Young-joo Kim) announced it made the joint sales agreement of 3 diabetes treatments and 2 hyperlipidemia treatments with MSD Korea.